Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral left between 1975 and 1989

Autor: Jean-Marc Hattchouel, R. Lancar, Ngoc An Lê, Antoine Andremont, Cyrille Tancrede, Monique G. Lê, Sophie Baron, Tahereh Tavakoli, Marie-Françoise Daniel
Rok vydání: 1996
Předmět:
Zdroj: Clinical Microbiology and Infection. 1:160-167
ISSN: 1198-743X
DOI: 10.1111/j.1469-0691.1996.tb00547.x
Popis: Objective To study the trends in mortality over 15 years in hospitalized cancer patients with bloodstream infection. Methods The yearly incidence rates and risk of death, by type of microorganism, were calculated for 4268 cancer patients hospitalized between 1975 and 1989 in a French cancer referral left. The relative risk of death (RR) associated with each type of microorganism was estimated using the proportional hazards model, taking into account age, hospital ward, underlying disease, geographical origin and year of the first positive blood culture. Results The incidence of these infections was five-fold higher in 1989 than in 1975. The largest increases were for coagulase-negative staphylococci (CNS), yeasts and Staphylococcus aureus. For the 3756 patients who had a single-microorganism bloodstream infection, the risk of death compared with that of patients with CNS infection was significantly increased in those with Pseudomonadaceae (RR = 5.0), yeasts (RR = 3.4), Enterobacteriaceae (RR = 3.2), S. aureus (RR = 2.8) and streptococci (RR = 2.1). The risk of death was not significantly different between patients with a single or several positive blood cultures nor between those with nosocomial or non-nosocomial infections. When the study period was divided in two time periods (1975 to 1982 vs 1983 to 1989), a significant variation ( p = 0.001) in risk of death associated with the different microorganisms was observed. Most risks were lower from 1983 to 1986 than before 1982. This decrease reached 60% for both S. aureus and Pseudomonadaceae. Conclusions These data support of continuing use of aggressive empirical antimicrobial therapy for cancer patients with fever.
Databáze: OpenAIRE